TO THE EDITOR:

Philadelphia chromosome (Ph)-like/BCR-ABL1–like acute lymphoblastic leukemia (ALL; Ph-like ALL) defines a subgroup of B-cell precursor ALL (B-ALL) lacking the BCR-ABL1 fusion, with a similar gene-expression profile to BCR-ABL1+ ALL and high risk of relapse.1-3  Ph-like ALL represents a genetically heterogeneous group, including a number of fusions, which involve the ABL-class genes: PDGFRB/A, CSF1R, ABL1, and ABL2.4-6  Preclinical studies have shown that leukemic cells from patients with these fusions respond well to tyrosine kinase inhibitors (TKIs), which has been confirmed in a number of patients, particularly those with EBF1-PDGFRB fusions.7-10  Here, we focus on the genetic and clinical features of a rare subset of ABL-class patients with the SSBP2-CSF1R fusion. In particular, we reveal the diversity of cytogenetic changes, giving rise to the fusion, highlighting that awareness of...

REFERENCES

REFERENCES
1.
Den Boer
ML
,
van Slegtenhorst
M
,
De Menezes
RX
, et al
.
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
.
Lancet Oncol
.
2009
;
10
(
2
):
125
-
134
.
2.
Mullighan
CG
,
Su
X
,
Zhang
J
, et al;
Children’s Oncology Group
.
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia
.
N Engl J Med
.
2009
;
360
(
5
):
470
-
480
.
3.
Boer
JM
,
den Boer
ML
.
BCR-ABL1-like acute lymphoblastic leukaemia: from bench to bedside
.
Eur J Cancer
.
2017
;
82
:
203
-
218
.
4.
Roberts
KG
,
Li
Y
,
Payne-Turner
D
, et al
.
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia
.
N Engl J Med
.
2014
;
371
(
11
):
1005
-
1015
.
5.
Roberts
KG
,
Morin
RD
,
Zhang
J
, et al
.
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia
.
Cancer Cell
.
2012
;
22
(
2
):
153
-
166
.
6.
Boer
JM
,
Steeghs
EM
,
Marchante
JR
, et al
.
Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia
.
Oncotarget
.
2017
;
8
(
3
):
4618
-
4628
.
7.
Lengline
E
,
Beldjord
K
,
Dombret
H
,
Soulier
J
,
Boissel
N
,
Clappier
E
.
Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion
.
Haematologica
.
2013
;
98
(
11
):
e146
-
e148
.
8.
Weston
BW
,
Hayden
MA
,
Roberts
KG
, et al
.
Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia
.
J Clin Oncol
.
2013
;
31
(
25
):
e413
-
e416
.
9.
Schwab
C
,
Ryan
SL
,
Chilton
L
, et al
.
EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications
.
Blood
.
2016
;
127
(
18
):
2214
-
2218
.
10.
Cario
G
,
Leoni
V
,
Conter
V
,
Baruchel
A
,
Schrappe
M
,
Biondi
A
.
BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy
.
Haematologica
.
2020
;
105
(
9
):
207019
.
11.
van der Veer
A
,
Waanders
E
,
Pieters
R
, et al
.
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL
.
Blood
.
2013
;
122
(
15
):
2622
-
2629
.
12.
Schwab
C
,
Harrison
CJ
.
Advances in B-cell precursor acute lymphoblastic leukemia genomics
.
HemaSphere
.
2018
;
2
(
4
):
e53
.
13.
Reshmi
SC
,
Harvey
RC
,
Roberts
KG
, et al
.
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group
.
Blood
.
2017
;
129
(
25
):
3352
-
3361
.
You do not currently have access to this content.

Sign in via your Institution

Sign In